Compare RLAY & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLAY | POET |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2020 | 2008 |
| Metric | RLAY | POET |
|---|---|---|
| Price | $13.50 | $14.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | 3.8M | ★ 59.4M |
| Earning Date | 05-05-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | $848.96 |
| Revenue Next Year | $324.03 | $700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $2.83 | $3.87 |
| 52 Week High | $17.32 | $20.65 |
| Indicator | RLAY | POET |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 57.45 |
| Support Level | $11.75 | $5.50 |
| Resistance Level | $17.32 | $15.50 |
| Average True Range (ATR) | 0.94 | 2.20 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 49.61 | 54.99 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.